Spectral AI
- Company typePublic
- Founded2013
- HeadquartersDallas, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Spectral AI firmographics
Firmographics- Name
- Spectral AI
- Legal name
- Spectral AI, Inc.
- Website
- https://spectral-ai.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Spectral AI industry classification
Industry- Product category
- AI Wound Care Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Spectral AI is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Spectral AI business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Government R&D Contract Revenue (BARDA / DoD): Primary current revenue stream from non-dilutive U.S. government research contracts including BARDA Project BioShield contract valued up to $150M (with $54.9M committed plus additional $31.7M advanced funding and company co-investment of $9.7M); also includes Defense Health Agency and Department of Defense contracts. R&D revenue was $4.0M in Q1 2026 versus $6.7M in Q1 2025, declining as base BARDA phase concluded.
- DeepView System Hardware Sales (Planned Commercial Launch): Anticipated commercial sales of the DeepView System to U.S. hospitals/burn centers following FDA De Novo Classification in May 2026; expected first commercial sales by year-end 2026 with 2026 revenue guidance of approximately $18.5 million.
- Equity & Debt Capital Raises: Funding from public/private placement ($7.6M offering in October 2025) and debt financing (up to $15M from Avenue Venture Opportunities Fund II) used to support commercialization and product development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Quote-based / not publicly disclosed; device sold by or on the order of a physician |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels10 records
Spectral AI product offering
Product offeringCore offering
Spectral AI develops and sells the DeepView AI System, a medical device that combines proprietary multispectral imaging (8 wavelengths across 400-900 nm) with proprietary AI algorithms trained on a 340+ billion data point burn wound database to deliver objective, Day-One binary predictions of wound healing potential. The system is FDA De Novo cleared for burn wound assessment (May 2026), UKCA authorized (February 2024), and supported by the portable DeepView SnapShot imaging platform; primary customers are hospitals, burn centers, NHS trusts, and U.S. government agencies.
Product overview
Spectral AI's offering centers on the DeepView AI® System, a single unified AI-powered predictive wound imaging platform that combines proprietary multispectral imaging hardware with deep learning algorithms to deliver Day-One wound healing predictions. The platform is delivered through the DeepView SnapShot® Imaging Platform (the portable hardware backbone) and is configured for multiple clinical indications through branded variants, including DeepView AI®-Burn (the FDA De Novo cleared thermal burn wound assessment device in the US and UKCA-marked device in the UK) and the DFU application for diabetic foot ulcers. The technology stack integrates 8-wavelength multispectral imaging (400-900nm), proprietary AI algorithms trained on over 340 billion data points from the world's largest burn biopsy tissue database, and optional EHR connectivity, delivering a binary healing prediction (healing vs non-healing) in approximately 20-25 seconds following a 0.2-second image acquisition. Spectral AI also maintains a clinical application pipeline exploring additional indications such as venous leg ulcer, critical limb ischemia, AI-guided therapy, AI-3D wound measurement, AI-digital health, and AI-cosmetics.
Differentiator
Problem solved
Functional benefit
Brands
- DeepView: AI-powered wound assessment and imaging platform combining multispectral imaging with proprietary AI algorithms to predict wound healing potential for burn wounds and diabetic foot ulcers.
- DeepView SnapShot
Products and services
- DeepView AI System An AI-based wound assessment and imaging platform that combines proprietary multispectral imaging with deep learning to deliver objective, Day-One binary predictions of wound healing potential for clinicians. FDA De Novo cleared for the burn indication in May 2026 and UKCA marked since February 2024; image acquisition takes 0.2 seconds and AI classification output is delivered in approximately 20-25 seconds. Achieved 92% accuracy in predicting burn wound healing potential compared with 50-70% clinician visual assessment. Sold by or on the order of a physician.
- DeepView SnapShot Imaging Platform A universal, portable hardware imaging platform that powers the DeepView AI System across multiple clinical indications and healthcare settings. Features multispectral camera capture with 8 unique wavelengths (400-900 nm), point-of-care bedside operation, rapid 0.2-second non-contact image acquisition, optional EHR connectivity, and supports burn, DFU, VLU, CLI, and AI-guided therapy indications.
Quantifiable outcome
- 92% accuracy on Day One in predicting if a burn wound will heal or not
- +5 more outcomes
Companies that use Spectral AI
Customer profileNamed customers5 records
Ideal customer profiles3 records
Spectral AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature7 records
Spectral AI partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- American Board of Wound Management FoundationminorCo-marketing / awareness partner during the 10th Annual Wound Healing Awareness Month in June 2026; joint campaign highlighting FDA De Novo Classification of the DeepView System for burn wound assessment.
- American Burn Association (ABA)minorJoint participation in National Burn Awareness Week 2026 (Feb 1-7, 2026), emphasizing burn prevention in workplaces; Spectral AI has been a regular participant at ABA Annual Meetings (e.g., 2026 Orlando meeting).
- British Burn Association (BBA)coreAnnual conference partner; Spectral AI participated in the 2025 BBA Annual Meeting (UK hospitals presented DeepView findings) and the 2026 BBA Annual Conference (June 17-19, 2026, Nottingham Trent University), where Dr. Jeffrey Carter won first prize for presentation on multispectral imaging with AI for burn wounds.
- Children's Burns Trust (CBT)minorSpectral AI is a 'Proud Sponsor' of Children's Burns Trust in the UK, supporting burn prevention campaigns such as National Burn Awareness Day and Child Safety Week and helping reduce burn injuries to children.
Scale indicators12 records
Recent moves8 records
Expansion highlights6 records
Spectral AI competitors and assessment
Company assessmentDirect peers
- MolecuLight: MolecuLight develops handheld point-of-care wound imaging devices using fluorescence to detect bacterial load and wound characteristics, targeting burn centers, wound clinics, and hospitals. Directly comparable to Spectral AI in terms of handheld form factor, point-of-care wound assessment, and burn/wound clinician customer base.
- Swift Medical: Swift Medical (now Swift) provides AI-powered smartphone wound measurement and imaging software widely used in wound care clinics and home health. Highly comparable as an AI-driven wound imaging platform serving similar clinical customers with similar predictive/measurement use cases.
- Tissue Analytics (a Net Health company): Tissue Analytics, now part of Net Health, provides AI-enabled smartphone wound imaging and documentation used across hospital wound care and post-acute settings. Directly comparable in AI wound imaging, EHR integration, and burn/DFU workflows.
- ARANZ Medical: ARANZ Medical's Silhouette system provides 3D wound measurement and documentation for wound care and clinical research. Comparable in wound imaging hardware and clinical decision support for wound healing assessment.
- eKare: eKare offers 3D wound imaging and AI-based wound measurement for hospitals, research, and clinical trials. Comparable AI-powered wound imaging platform serving similar clinical workflows in burn and chronic wound care.
Broad incumbents
- HeartFlow: HeartFlow is a commercial-stage medical imaging AI SaMD company providing non-invasive coronary disease assessment. Comparable as a clinically validated, FDA-cleared AI imaging SaMD with a similar enterprise sales motion into hospitals and specialist clinicians.
- Aidoc: Aidoc is a broad medical imaging AI platform with multiple FDA-cleared algorithms for radiology triage and notification. Comparable in AI medical imaging SaMD model, hospital enterprise sales motion, and clinical decision support positioning.
- Viz.ai: Viz.ai develops AI-powered imaging software for time-sensitive conditions (e.g., stroke triage), with an FDA-cleared SaMD model sold into hospitals. Comparable as a specialized clinical imaging AI SaMD with an enterprise hospital sales motion.
- Smith+Nephew: Smith+Nephew is a global medical device company with a large Advanced Wound Management portfolio. Comparable as a broad incumbent in wound care addressing burn and chronic wound customers, providing context for market scale and competitive intensity.
- Mölnlycke Health Care: Mölnlycke is a major wound care and surgical solutions company with significant global presence in burn and chronic wound management. Comparable as a broad incumbent in the wound care ecosystem serving similar clinician customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Spectral AI social profiles
Digital presenceSpectral AI compliance and trust
Trust signalCompliance2 records
Spectral AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spectral AI leadership team
Management profileNumber of profiles
Profiles8 records
Spectral AI subsidiaries and ownership
Company hierarchySubsidiaries2 records
Spectral AI funding detail
Funding detailFunding overview
Funding rounds11 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spectral AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spectral AI
What does Spectral AI do?
Spectral AI develops and sells the DeepView AI System, a medical device that combines proprietary multispectral imaging (8 wavelengths across 400-900 nm) with proprietary AI algorithms trained on a 340+ billion data point burn wound database to deliver objective, Day-One binary predictions of wound healing potential. The system is FDA De Novo cleared for burn wound assessment (May 2026), UKCA authorized (February 2024), and supported by the portable DeepView SnapShot imaging platform; primary customers are hospitals, burn centers, NHS trusts, and U.S. government agencies.
Is Spectral AI a public or private company?
Spectral AI is a public company. It is classified as public and is currently operating.
When was Spectral AI founded?
Spectral AI was founded in 2013. It employs 51 to 100 people.
Where is Spectral AI based?
Spectral AI is headquartered in Dallas, United States, in the North America region.
How does Spectral AI make money?
Three revenue lines are on record. Government R&D Contract Revenue (BARDA / DoD) is the primary driver. The others are deepView System Hardware Sales (Planned Commercial Launch) and equity & Debt Capital Raises.
Who are Spectral AI's main competitors?
Direct peers on record are MolecuLight, Swift Medical, Tissue Analytics (a Net Health company), ARANZ Medical and eKare. Broad incumbents are HeartFlow, Aidoc, Viz.ai, Smith+Nephew and Mölnlycke Health Care.
Does Spectral AI have an API?
No public API is recorded for Spectral AI.
What industry is Spectral AI in?
Spectral AI's product category is AI Wound Care Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 334510 and its SIC code is 3841.